BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10078642)

  • 21. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
    Caster JM; Falchook AD; Hendrix LH; Chen RC
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate brachytherapy: treatment strategies.
    Stone NN; Stock RG
    J Urol; 1999 Aug; 162(2):421-6. PubMed ID: 10411050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting prostate specific antigen failure after radical retropubic prostatectomy for T1c prostate cancer.
    Ou YC; Chen JT; Yang CR; Cheng CL; Ho HC; Ko JL; Hsieh YS
    Jpn J Clin Oncol; 2002 Dec; 32(12):536-42. PubMed ID: 12578903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
    Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of Gleason scores between needle-core biopsy and radical prostatectomy specimens in patients with prostate cancer.
    Hsieh TF; Chang CH; Chen WC; Chou CL; Chen CC; Wu HC
    J Chin Med Assoc; 2005 Apr; 68(4):167-71. PubMed ID: 15850066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical utility of endorectal MRI in determining PSA outcome for patients with biopsy Gleason score 7, PSA Cheng GC; Chen MH; Whittington R; Malkowicz SB; Schnall MD; Tomaszewski JE; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):64-70. PubMed ID: 12504037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
    Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
    J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary Gleason grade 4 impact on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer.
    Uesugi T; Saika T; Edamura K; Nose H; Kobuke M; Ebara S; Abarzua F; Katayama N; Yanai H; Nasu Y; Kumon H
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e219-23. PubMed ID: 21640517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era.
    D'Amico AV; Whittington R; Malkowicz SB; Weinstein M; Tomaszewski JE; Schultz D; Rhude M; Rocha S; Wein A; Richie JP
    J Urol; 2001 Dec; 166(6):2185-8. PubMed ID: 11696732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer.
    D'Amico AV; Whittington R; Malkowicz B; Schnall M; Schultz D; Cote K; Tomaszewski JE; Wein A
    J Urol; 2000 Sep; 164(3 Pt 1):759-63. PubMed ID: 10953141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy.
    Goluboff ET; Heitjan DF; DeVries GM; Katz AE; Benson MC; Olsson CA
    J Urol; 1997 Nov; 158(5):1876-8; discussion 1878-9. PubMed ID: 9334621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A solitary positive prostate cancer biopsy does not predict a unilateral lesion in radical prostatectomy specimens.
    Koie T; Mitsuzuka K; Narita S; Yoneyama T; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C
    Scand J Urol; 2015 Apr; 49(2):103-7. PubMed ID: 25165894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer with large glands treated with 3-dimensional computerized tomography guided pararectal brachytherapy: up to 8 years of followup.
    Koutrouvelis PG; Lailas N; Katz S; Sehn J; Gil-Montero G; Khawand N
    J Urol; 2003 Apr; 169(4):1331-6. PubMed ID: 12629354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
    Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Huland E; Scardino PT; Kattan MW; Huland H
    J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.